Myasthenia Gravis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Myasthenia Gravis – Drugs In Development, 2024 report and make more profitable business decisions.
Myasthenia gravis is an autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia, and difficulty swallowing, chewing, and speaking. Treatment includes immunosuppressants, corticosteroids, and surgery.
The Myasthenia Gravis drugs in development market research report provide comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Myasthenia Gravis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 63 molecules, with 60 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Myasthenia Gravis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Myasthenia Gravis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Myasthenia Gravis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AffaMed Therapeutics US IncAhead Therapeutics SL
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Alpine Immune Sciences Inc
Amgen Inc
Amneal Pharmaceuticals Inc
Amplo Biotechnology Inc
AnTolRx Inc
Argenx SE
Astria Therapeutics Inc
Beijing Mabworks Biotech Co Ltd
BioXpress Therapeutics SA
Cabaletta Bio Inc
CANbridge Life Sciences Ltd
Cartesian Therapeutics Inc
Catalyst Pharmaceuticals Inc
Chugai Pharmaceutical Co Ltd
Cour Pharmaceuticals Development Co Inc
CSPC NBP Pharmaceutical Co Ltd
DAS Therapeutics Inc
Dianthus Therapeutics Inc
F. Hoffmann-La Roche Ltd
GRO Biosciences Inc
HanAll Biopharma Co Ltd
ImmunAbs Inc
Immunovant Inc
Johnson & Johnson
KIMS Pharmaceutical Co Ltd
Kyverna Therapeutics Inc
Lan-yi Therapeutics Ltd
Merck KGaA
MetVital Inc
MimiVax LLC
Mitsubishi Tanabe Pharma Corp
Nihon Pharmaceuticals Co Ltd
NMD Pharma AS
Novartis AG
NovelMed Therapeutics Inc
Oak Hill Bio Inc
Pfizer Inc
PlateletBio
Ra Pharmaceuticals Inc
Rallybio Corp
ReceptoPharm Inc
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Takeda Pharmaceutical Co Ltd
Tasly Biopharmaceuticals Co Ltd
Taxon Therapeutics Ltd
Toleranzia AB
Turgut Ilaclari AS
UCB SA
University of Kansas Medical Center
University of Pennsylvania
Zai Lab Ltd
Zhejiang University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Myasthenia Gravis reports